Abstract: The present invention provides fusion peptides, compositions, methods and kits for treating, reducing the risk of, lessening the severity of, preventing, or delaying the onset of amyloid-related disorders, such as Alzheimer's disease and HIV associated neurocognitive impairment.

Abstract: The present invention relates to a chimeric protein that includes an N-terminus coupled to a C-terminus, where the N-terminus includes a portion of a paracrine fibroblast growth factor (“FGF”) and the C-terminus includes a C-terminal portion of an FGF21 molecule. The portion of the paracrine FGF is modified to decrease binding affinity for heparin and/or heparan sulfate compared to the portion without the modification. The present invention also relates to pharmaceutical compositions including chimeric proteins according to the present invention, methods for treating a subject suffering from diabetes, obesity, or metabolic syndrome, and methods of screening for compounds with enhanced binding affinity for the ?Klotho-FGF receptor complex involving the use of chimeric proteins of the present invention.

Abstract: The present invention relates to a chimeric protein that includes an N-terminus coupled to a C-terminus, where the N-terminus includes a portion of a paracrine fibroblast growth factor (“FGF”) and the C-terminus includes a C-terminal portion of an FGF19 molecule. The portion of the paracrine FGF is modified to decrease binding affinity for heparin and/or heparan sulfate compared to the portion without the modification. The present invention also relates to pharmaceutical compositions including chimeric proteins according to the present invention, methods for treating a subject suffering from diabetes, obesity, or metabolic syndrome, and methods of screening for compounds with enhanced binding affinity for the ?Klotho-FGF receptor complex involving the use of chimeric proteins of the present invention.

Abstract: The invention relates to truncated BMP-7 growth factors and variants thereof. The invention also relates to methods of making and using the truncated BMP-7 growth factors.

Abstract: The present invention relates to a water-soluble expression and a purification method of a human granulocyte colony-stimulating factor (hGCSF) recombinant protein having biological activities using an N-terminal tag, and provides a recombinant expression vector containing a solubility enhancing tag and a hGCSF gene. In addition, provided are: a recombinant microorganism transformed with the recombinant expression vector; a method for producing a hGCSF recombinant protein (rhGCSF); and a rhGCSF produced by the production method.

Abstract: This disclosure relates to recombinant proteins, vectors, and methods of treating neurological conditions by exposing neurons to an opsin and luciferase in the presence of a luciferin. In certain embodiments, the disclosure relates to treating or preventing epilepsy or seizures comprising administering an effective amount of a vector that encodes an opsin and luciferase in combination with a luciferin to a subject in need thereof.

Abstract: The present invention provides, in particular embodiments, for modified recombinant T cell receptor (TCR) ligands (RTLs) comprising a MHC class I or MHC class II component. The modified RTLs have redesigned surface features that preclude or reduce aggregation, wherein the modified molecules retain the ability to bind Ag-peptides, target antigen-specific T cells, inhibit T cell proliferation in an Ag-specific manner and have utility to treat, inter alia, autoimmune disease and other conditions mediated by antigen-specific T cells in vivo.

Abstract: Disclosed is a method for producing proteins having factor VIII procoagulant activity in serum-free medium by in vitro culturing of mammalian cells, wherein the serum-free medium contains an inhibitor against the protease released from cultured cells. In accordance with this invention, the inhibitor can protect the cleavage of a target protein during cultivation and increase homogeneity of a target molecule, wherein the inhibitor can be a dextran sulfate. This invention also relates to a method of purifying target molecules from the culture medium containing both a target molecule and selected inhibitors by affinity chromatography.

Abstract: IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacement compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases.

Abstract: Campylobacter jejuni is a leading cause of bacterial food-borne diseases in humans, ranging from acute diarrheal disease to neurological disorders. An isolated or purified antibody or fragment thereof specific to C. jejuni is described. The antibody or fragment thereof binds to a flagellar protein and reduces motility of C. jejuni. The antibody or fragment thereof is derived from a heavy chain IgG variable domain fragment (VHH) of a camelid animal immunized with C. jejuni flagellar protein. A multivalent form, as well as a phage format, of the antibody or fragment thereof is described. Methods of reducing presence of C. jejuni in an animal or an animal environment, methods and formulations for treating C. jejuni infection, and method of detecting C. jejuni are also described.

Abstract: Provided are chimeric, camelid-human (e.g., llama-human) polypeptides comprising a first antigenic polypeptide portion and a second antigenic polypeptide portion wherein the first antigenic portion is a derived from a first portion of a camelid (e.g., llama) and the second antigenic portion is a human polypeptide homolog of a second portion of the camedid antigen. The chimeric polypeptides are useful inter alia for epitope mapping and generation of antibodies that bind to a desired region of human antigen.

Abstract: The present invention provides methods for reducing glycoprotein aggregation by optimizing the number of O-linked glycosylation sites.

Abstract: A method of treating a hemolytic disorder in a subject in need thereof includes administering to the subject a therapeutically effective amount of an antibody that binds to a component of alternative pathway C3 convertase and selectively inhibits C3a, C5a, C3b, C5b, and C5b-9 produced exclusively by the alternative pathway, without inhibiting any of the classical pathway's ability to produce C3a, C5a, C3b, C5b, and C5b-9.

Abstract: Antibodies and antigen binding fragments thereof that bind to human protein tyrosine phosphatase beta (HPTP?), and uses thereof.

Abstract: The disclosure provides novel molecules related to growth and differentiation factor-8 (GDF-8), in particular mouse and humanized antibodies, and antibody fragments, including those that inhibit GDF-8 activity and signaling in vitro and/or in vivo. The disclosure also provides methods for diagnosing, treating, ameliorating, preventing, prognosing, or monitoring degenerative orders of muscle, bone, and insulin metabolism, etc., in particular amyotrophic lateral sclerosis (ALS). In addition, the disclosure provides pharmaceutical compositions for the treatment of such disorders by using the antibodies, polypeptides, polynucleotides, and vectors of the invention.

Abstract: The present invention provides antibodies that bind to angiopoietin-2 (Ang-2) and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human Ang-2. The antibodies of the invention are useful, inter alia, for the treatment of diseases and disorders associated with one or more Ang-2 biological activities including angiogenesis.

Abstract: The present invention is directed to therapeutic methods using IL-6 antagonists such as antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat thrombosis in diseases associated with abnormal blood coagulation or fibrinolysis. In preferred embodiments these patients will comprise those exhibiting elevated D-dimer or other coagulation cascade related proteins and optionally will further exhibit elevated C reactive protein prior to treatment. The subject therapies also may include the administration of other actives such as chemotherapeutics, anti-coagulants, statins, et al.

Abstract: M-CSF-specific RX1-based or RX-1 derived antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating bone loss in a subject afflicted with an osteolytic disease.

Abstract: Methods and compositions for modulating blood-neural barrier (BNB) for the treatment of CNS conditions such as edema, and for increased drug delivery efficacy across the BNB. The present invention further relates to improved tPA treatment of ischemic cerebrovascular and related diseases in combination with antagonism of the PDGF signaling pathway. The inventive method and composition is particularly suitable for conjunctive therapy of ischemic stroke using tPA and an anti-PDGF-C antagonist or an anti-PDGFR-? antagonist.

Abstract: Provided are compositions and methods relating to human CD30L antigen binding proteins. Compositions described herein include: human CD30L antigen binding proteins, polynucleotides encoding human CD30L antigen binding proteins, vectors comprising these polynucleotides, host cells, and pharmaceutical compositions. Methods of making and using each of these compositions are also provided.

Abstract: Methods of inducing T cell proliferation and expansion in vivo for treating conditions wherein antigen-specific T cell immune response are therapeutically desirable such as cancer, infection, inflammation, allergy and autoimmunity and for enhancing the efficacy of vaccines are provided. These methods comprise the administration of at least one CD27 agonist, preferably an agonistic CD27 antibody, alone or in association with another moiety such as immune stimulant or immune modulator such as an anti-CD40, OX-40, 4-1BB, or CTLA-4 antibody or an agent that depletes regulatory cells, or a cytokine. These mono and combination therapies may also optionally include the administration of a desired antigen such as a tumor antigen, an allergen, an autoantigen, or an antigen specific to an infectious agent or pathogen against which a T cell response (often CD8+) is desirably elicited.

Abstract: The present application relates to compositions of humanized and deimmunized anti-endoglin antibodies and antigen-binding fragments thereof. One aspect relates to antibodies having one or more modifications in at least one amino acid residue of at least one of the framework regions of the variable heavy chain, the variable light chain or both. Another aspect relates to anti-endoglin antibodies which inhibit or treat fibrosis.

Abstract: Antibody drug conjugates (ADC's) that bind to 158P1D7 protein and variants thereof are described herein. 158P1D7 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in glioblastoma, lung cancer, bladder cancer, and breast cancer. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.

Abstract: The invention provides anti-GPC3 antibodies and immunoconjugates and methods of using the same.

Abstract: Antibodies and antigen-binding fragments of antibodies that bind OV064 are disclosed. The antibodies bind an extracellular domain of OV064. Some of the antibodies and antigen-binding fragments bind an epitope on OV064 sufficient to induce internalization. In some embodiments, the antibodies are humanized, chimeric or human. Nucleic acids and vectors encoding the antibodies or portions thereof, recombinant cells that contain the nucleic acids, and compositions comprising the antibodies or antigen-binding fragments are also disclosed. The invention also provides therapeutic and diagnostic methods utilizing the antibodies and antigen-binding fragments provided herein.

Abstract: The present invention relates to bispecific antibodies comprising at least one antigen binding site specific for DR5 and at least one antigen binding site specific for FAP, antibodies specific for DR5, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Abstract: The specification describes the sequences for antibodies that recognize the HLA-A2-restricted peptide PR-1 in the context of HLA presentation on the surface of cancer cells. Use of these antibodies in the diagnosis and treatment of cancer and immune-related diseases are also provided.

Abstract: The present invention relates to monoclonal antibodies targeting the membrane bound IgM (mIgM) of the B-cell receptor complex found in B-cell lymphomas and leukemias. Monoclonal antibodies designated mAb4-2b, mAb1-1, mAb2-2b and mAb3-2b were produced by hybridoma cell lines (ATCC deposit no. PTA-121716), (ATCC deposit no. PTA-121719), (ATCC deposit no. PTA-121717), and (ATCC deposit no. PTA-121718), respectively. Another aspect of the present invention is the use of anti-B-Cell mIgM antibodies in the treatment of B-cell malignancies, including B-cell lymphomas and leukemias.

Abstract: The invention provides novel bispecific monoclonal antibodies carrying a different specificity for each binding site of the immunoglobulin molecule and methods for producing novel bispecific monoclonal antibodies carrying a different specificity for each binding site of the immunoglobulin molecule. The antibodies are composed of a single heavy chain and two different light chains, one containing a Kappa constant domain and the other of a Lambda constant domain. The invention provides methods for the isolation of antibodies of different specificities but sharing a common heavy chain. The invention also provides methods for the controlled co-expression of two light chains and a single heavy chain leading to the assembly of monospecific and bispecific antibodies.

Abstract: The present invention relates to a method of producing a solid coated carrier carrying biological material. Furthermore, the invention relates to a solid coated carrier to which biological material is attached and uses of the solid coated carrier for the preparation of a medical product. Moreover, the invention provides a method for the contacting, filtration or cleaning of blood, lymph or liquor cerebrospinalis of a patient, a method for the diagnosis of a disease and a diagnostic composition.

Abstract: This invention relates a cellulose solution comprising cellulose and at least one tetraalkylammonium alkylphosphate and processes to produce the cellulose solution. Another aspect of this invention relates to shaped articles prepared from a cellulose solution comprising cellulose and at least one tetraalkylammonium alkylphosphate. Another embodiment of this invention relates to compositions comprising derivatives of cellulose prepared from a cellulose solution comprising at least one tetraalkylammonium alkylphosphate. Another embodiment of this invention relates to compositions comprising regioselectively substituted cellulose esters prepared from a cellulose solution comprising cellulose and at least one tetraalkylammonium alkylphosphate. In another embodiment of the invention, the cellulose esters of the present invention are used as protective and compensation films for liquid crystalline displays.

Abstract: Provided are a method for producing a water-soluble cellulose ether having a low degree of polymerization and enhanced whiteness, and the like. The method includes the steps of: bringing a pulp powder having a multiplication product of less than 0.004 mm2 which is obtained by multiplying a number-average fiber length by a number-average fiber width, each measured with a Kajaani fiber length analyzer, into contact with an alkali metal hydroxide to obtain an alkali cellulose; reacting the alkali cellulose with an etherifying agent to obtain a crude water-soluble cellulose ether having a high degree of polymerization; purifying the crude water-soluble cellulose ether; drying the purified water-soluble cellulose ether; grinding the dried water-soluble cellulose ether into a water-soluble cellulose ether powder; and depolymerizing the water-soluble cellulose ether powder to obtain the water-soluble cellulose ether having a low degree of polymerization.

Abstract: An object of the present invention is to provide a living radical polymerization catalyst that is excellent in terms of safety and cost, and is applicable to various vinyl monomers, and to provide a method for producing a polymer using this living radical polymerization catalyst. The living radical polymerization catalyst contains at least one member selected from the group consisting of alkali metal halide compounds and alkaline earth metal halide compounds.

Abstract: The present invention relates to a continuous or semi-continuous freeze coagulation process for aqueous polymer dispersions, wherein said process comprises a freezing step and a solid-liquid separation step and is further characterized in that it comprises the further step of admixing water and/or water vapor between the freezing step and the solid-liquid separation step.

Abstract: This invention relates to a process for forming a long-chain branched polymer and a long-chain branched polymer resulting from the process. The process comprises reacting (a) a polyolefin base polymer with (b) a coupling agent comprising a polymeric coupling agent, optionally blended with a molecular coupling agent, the polymeric coupling agent being a modified polyolefin having a reactive coupling group at one or more terminal ends of the modified polyolefin chain, to couple the polyolefin base polymer (a) with the coupling agent (b) to form a long-chain branched polymer having a long-chain branching and/or higher surface energy relative to the polyolefin base polymer.

Abstract: A fluid dynamic model having at least 5,000,000 cells of the portion of a gas phase reactor from the exit of the condenser to a half a reactor diameter above the bed plate is useful in determining the design of the bottom surface or support structure for a bed plate to minimize liquid pooling below and above the bed plate when operating in condensing mode.

Abstract: Method for switching between steady-state and non-steady-state operations of a process for the production of a polymer by polymerization of a monomer in the presence of a comonomer and/or hydrogen. The process includes (a1) at non-steady-state controlling the process based on the ratio of comonomer to monomer in the reactor, and (b1) at steady-state controlling the process based on the flow ratio of comonomer to monomer to the reactor, and/or (a2) at non-steady-state controlling the process based on the ratio of hydrogen to monomer in the reactor, and (b2) at steady-state controlling the process based on the flow ratio of hydrogen to monomer to the reactor.

Abstract: The invention relates to a process for the preparation of a procatalyst suitable for preparing a catalyst composition for olefin polymerization. The invention also relates to a procatalyst obtained or obtainable by the process. The invention further relates to the use of a benzamide as an activator in the preparation of a Ziegler-Natta procatalyst. The invention also relates to a process for the preparation of polyolefins. The invention also relates to a polyolefin. The invention further relates to a shaped article.

Abstract: The present invention relates to a thermoplastic block copolymer comprising at least one PA block and at least one PB block. The PA block represents a polymer block comprising one or more units of monomer A, and the PB block represents a polymer block comprising one or more units of monomer B. Monomer A is a vinyl, acrylic, diolefin, nitrile, dinitrile, acrylonitrile monomer, a monomer with reactive functionality, or a crosslinking monomer. Monomer B is a radically polymerizable triglyceride or mixtures thereof, typically in the form of a plant or animal oil. The present invention also relates to a method of preparing a thermoplastic block copolymer or novel thermoplastic statistical copolymers by polymerizing a radically polymerizable monomer with a radically polymerizable triglyceride or mixtures thereof via reversible addition-fragmentation chain-transfer polymerization (RAFT), in the presence of an free radical initiator and a chain transfer agent.

Abstract: Catalyst systems having both a metallocene catalyst component and a Ziegler-Natta component are disclosed. Such catalyst systems can contain a metallocene compound, an activator-support, an organoaluminum compound, and a Ziegler-Natta component comprising titanium supported on magnesium chloride.

Abstract: The present invention relates to a new transition metal compound based on cyclopenta[b]fluorenyl group, a transition metal catalyst composition containing the same and having high catalytic activity for preparing an ethylene homopolymer or a copolymer of ethylene and one ?-olefin, a method of preparing an ethylene homopolymer or a copolymer of ethylene and ?-olefin using the same, and the prepared ethylene homopolymer or the copolymer of ethylene and ?-olefin.

Abstract: The present invention relates to a hybrid supported metallocene catalyst. More specifically, the present invention relates to a hybrid supported metallocene catalyst using two or more different types or more of metallocene compounds, among which one type of the metallocene compounds shows a high polymerization activity even when it is supported, and thus the catalyst has an excellent activity and can be utilized in the polymerization of olefinic polymers having ultra-high molecular weight. Based on the hybrid supported metallocene catalyst of the present invention, an olefinic polymer having high molecular weight and the desired physical property can be prepared.

Abstract: This invention relates to a process to polymerize olefins, particularly to produce ethylene polymers with internal unsaturation structures.

Abstract: A vinylpyridine resin that is hardly pulverized and thermally decomposed such that the degradation of the catalytic activity is suppressed while having a pore volume and a specific surface area to maintain a sufficient catalytic activity, and also a method of manufacturing the vinylpyridine resin are provided. The resin represents: a volume ratio of the pores having a diameter of 3 through 5 nm to all the pores of not less than 4% and not more than 60%; a total pore volume of not less than 0.15 cc/g and not more than 0.35 cc/g; and a specific surface area of not less than 20 m2/g and not more than 100 m2/g. The resin can be manufactured by using a poor solvent and not less than 50 wt % and not more than 90 wt % of a good solvent as porous agent.

Abstract: The invention provides composite particles comprising core particles having organosilica particles disposed about the core particles. The invention also provides a process for making the composite particles.

Abstract: An elastomeric polymer, comprising (1) a hard segment in the amount of 10% to 60% by weight of the elastomeric polymer, wherein the hard segment includes a urethane, urea, or urethaneurea; and (2) a soft segment in the amount of 40% to 90% by weight of the elastomeric polymer, wherein the soft segment includes a polyisobutylene macrodiol and/or diamine. Additionally disclosed is a method of forming a polyisobutylene-based thermoplastic urethane, comprising the steps of (a) reacting a polyisobutylene macrodiol and/or diamine with a diisocyanate to form a first reaction mixture; (b) combining a metal catalyst and a chain extender with the first reaction mixture to create a second reaction mixture, a molar ratio of the metal catalyst to the diisocyanate being greater than 0.0:1 and less than or equal to 0.4:1; and (c) reacting the second reaction mixture for a period of time sufficient to form the polyisobutylene-based thermoplastic urethane.

Abstract: Radical polymerization techniques can be used to polymerize monomers that include a class of hydroxyaryl compounds so as to provide polymers that exhibit desirable properties including, but not limited to, reduced hysteresis. Compositions such as vulcanizates in which such polymers can be utilized and products such as tire components that incorporate and/or are manufactured from such compositions also are provided.

Abstract: Methods for making wet gels and dried gels therefrom are provided. The method for making a wet gel can include combining a hydroxybenzene compound, an aldehyde compound, and an additive to produce a reaction mixture. The additive can include a carboxylic acid, an anhydride, a homopolymer, a copolymer, or any mixture thereof. At least the hydroxybenzene compound and the aldehyde compound can be reacted to produce a wet gel. The reaction mixture can include about 10 wt % to about 65 wt % of the hydroxybenzene compound, about 5 wt % to about 25 wt % of the aldehyde compound, up to about 85 wt % of the carboxylic acid, up to about 40 wt % of the anhydride, up to about 40 wt % of the homopolymer, and up to about 40 wt % of the copolymer, where weight percent values are based on the combined weight of the hydroxybenzene compound, the aldehyde compound, and the additive.

Abstract: The present invention relates to a process for producing polyisocyanates comprising reacting an isocyanate component in the presence of a mono- or multinuclear complex of titanium, zirconium and/or hafnium as catalyst to give polyisocyanates having a content of iminooxadiazinedione groups of ?20 mol % based on the total amount of isocyanurate and iminooxadiazinedione groups. The present invention also provides polyisocyanates obtainable by the process according to the invention and both polyurethanes and polyureas obtainable by reacting the polyisocyanates with at least one hydroxy-functional or amino-functional component respectively.

Abstract: Process for preparing rigid polyurethane or urethane-modified polyisocyanurate foams from polyisocyanates and polyfunctional isocyanate-reactive compounds in the presence of blowing agents wherein the polyfunctional isocyanate-reactive compounds comprise a polyether polyol having a hydroxyl number of between 50 and 650 mg KOH/g obtained by reacting a polyfunctional initiator first with ethylene oxide and subsequently with propylene oxide wherein the propoxylation degree is between 0.33 and 2 mole propylene oxide per active hydrogen atom in the initiator and wherein the molar ratio of ethylene oxide to propylene oxide in said polyether polyol is at least 2.